888.666.2560

Latest News from Admune Therapeutics

Admune Therapeutics LLC is dedicated to improving the health and well-being of patients, providing effective solutions to hospitals and physicians, and to bettering our community and employees. To learn more about the latest developments from Admune Therapeutics, click on the links below.


Admune Therapeutics to be Acquired by Novartis October 21, 2015

DANVERS, Mass. – Admune Therapeutics LLC ("Admune"), a clinical-stage biotechnology company developing cytokine drugs for cancer immunotherapy, today announces that it has agreed to the sale of Admune to Novartis. The focus of the acquisition is Admune’s lead compound, Heterodimeric IL-15 (IL15:IL15Ra), a novel IL-15 agonist that may have broad... Read More >

Admune Announces the First-in-Human Study of Heterodimeric IL-15 (hetIL-15) with Broad Applications for Cancer Immunotherapy June 18, 2015

Initiation of Enrollment in the Phase I Study of hetIL-15 for the Treatment of Metastatic Cancers DANVERS, Mass. – Admune Therapeutics, a clinical-stage biotechnology company developing cytokine drugs for cancer immunotherapy, announced today that enrollment has initiated in a Phase I clinical trial evaluating the safety and efficacy of its lead... Read More >

Adding to Immune Function May 4, 2015

Admune Therapeutics LLC is developing a heterodimeric complex of IL-15 to boost the immune system’s response to cancer immunotherapies by increasing the number of antitumor lymphocytes overall and in the vicinity of tumors. Tumors’ responses to immunotherapy depend in part on the appropriate balance of immune cells that carry out an... Read More >